Article
Polygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome.
Kidney international - 1 Jun 2026
Tu Tiffany, Ochoa Alejandro, Sood Amika, Dabrik Ashley, Chryst-Stangl Megan, Lane Brandon, Wu Guanghong, Donovan Frank, Harper Ursula, Chandrasekharappa Settara, Esezobor Christopher, Solarin Adaobi, Hooper David, Sethna Christine, Amaral Sandra, Kallash Mahmoud, Rheault Michelle, Verghese Priya, Dharnidharka Vikas, Salmon Eloise, Weng Patricia, Srivastava Tarak, Seifert Michael E, Pruette Cozumel, Selewski David, Gibson Keisha, Hunley Tracy, Abeyagunawardena Asiri, Thalgahagoda Shenal, Bagga Arvind, Sinha Aditi, Webb Nicholas, Greenbaum Larry, Gharavi Ali, Kiryluk Krzysztof, Kretzler Matthias, Guay-Woodford Lisa, Sanna-Cherchi Simone, Bierzynska Agnieszka, Koziell Ania, Welsh Gavin, Saleem Moin, Rotimi Charles, Chambers Eileen, Chan Cliburn, Jackson Annette, Adeyemo Adebowale, Gbadegesin Rasheed
Abstract excerpt
INTRODUCTION: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are no current reliable predictors of therapy response at initial clinical presentation. METHODS: To evaluate predictors, we conducted genome-wide association...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.